相关实验视频
Updated: Jun 24, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
在重症成人中对密集葡萄糖控制进行患者级的元分析
Derick Adigbli1,2,3,4, Yang Li1, Naomi Hammond1,5
1Critical Care Division, The George Institute for Global Health, Sydney.
NEJM evidence
|June 12, 2024
概括
在重症患者中,强化血糖控制并没有降低死亡风险. 然而,这种方法显著增加了严重低血糖的风险,没有确定患者子组从中受益.
科学领域:
- 关键护理医学 关键护理医学
- 代谢障碍 代谢障碍 代谢障碍
- 临床试验中的临床试验.
背景情况:
- 密集血糖控制对重症患者死亡率的影响仍然不确定.
- 患者层面的元分析对于精确估计治疗效果至关重要.
研究的目的:
- 为了确定密集的血糖控制是否会降低严重病情的成年人死亡率.
- 评估二次结果,包括生存和治疗终止.
- 评估密集血糖控制的安全性,特别是严重的低血糖.
主要方法:
- 从20个随机试验 (14,171名参与者) 中汇集了个体患者数据.
- 主要结局:住院死亡率.
- 安全结果:严重的低血糖.
主要成果:
- 强化血糖控制 (n=7059) 与常规控制 (n=7049) 相比,没有显著降低住院死亡率 (风险比,1.02;P=0.52).
- 在各个子组中没有观察到治疗效果的异质性.
- 重度低血糖的风险在密集控制时显著增加 (风险比,3.38;P<0.0001).
结论:
- 在重症成人中,强化血糖控制与死亡率的降低无关.
- 严重低血糖的风险增加了密集的血糖控制.
- 没有任何特定的患者亚组显示强化血糖控制有好处.
相关概念视频
Diabetes: Management and Pharmacotherapy
260
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
260
Hypoglycemia and Glucagon
256
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
256
Diabetes: Symptoms, Diagnosis, and Complications
523
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
523
Insulin: Dosing Regimen and Adverse Effects
166
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
166
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189

